Kate McKinley

CIK: 0001979211

Transaction Breakdown

Open Market Buys (P)1 (25.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (75.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

RANI

Rani Therapeutics Holdings, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (4 total)

RANI
Rani Therapeutics Holdings, Inc.
Jun 3, 2026
Award(A)
Stock Option (Right to Buy)
Direct
805.5K shares-
RANI
Rani Therapeutics Holdings, Inc.
Aug 1, 2025
Award(A)
Employee Stock Option (Right to Buy)
Direct
120K shares-
RANI
Rani Therapeutics Holdings, Inc.
May 23, 2025
Award(A)
Stock Option (Right to Buy)
Direct
325K shares-
RANI
Rani Therapeutics Holdings, Inc.
Dec 13, 2024
Purchase(P)
Direct
18K shares at avg. $1.67$30K

		Type	Shares	Price		Ownership
Jun 3, 2026	RANI Rani Therapeutics Holdings, Inc.	Award(A) Stock Option (Right to Buy)	805,500	-	-	Direct
Aug 1, 2025	RANI Rani Therapeutics Holdings, Inc.	Award(A) Employee Stock Option (Right to Buy)	120,000	-	-	Direct
May 23, 2025	RANI Rani Therapeutics Holdings, Inc.	Award(A) Stock Option (Right to Buy)	325,000	-	-	Direct
Dec 13, 2024	RANI Rani Therapeutics Holdings, Inc.	Purchase(P)	17,960	$1.67	$29,993	Direct

1-4 of 4 transactions

About McKinley Kate

McKinley Kate (SEC CIK 0001979211) files insider reports with the SEC as Chief Business Officer of Rani Therapeutics Holdings, Inc. (RANI).

Signal8 holds 4 ownership filings by McKinley Kate, all Form 4s, filed between Dec 16, 2024 and Jun 5, 2026. Those filings report 4 transactions, from Dec 13, 2024 to Jun 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on McKinley Kate's filings is in SAN JOSE, CA.

Recent filings by McKinley Kate

Jun 3, 2026: Grant or award of RANI derivative securities (Form 4, code A).
Aug 1, 2025: Grant or award of RANI derivative securities (Form 4, code A).
May 23, 2025: Grant or award of RANI derivative securities (Form 4, code A).
Dec 13, 2024: Open-market purchase of RANI shares (Form 4, code P).

Other insiders filing for Rani Therapeutics Holdings, Inc. (RANI)

Imran Talat, Chief Executive Officer
Javadi Alireza, Chief Technical Officer
Gilson Michelle, Director
IMRAN MIR A, Director
Maestas Nicholas, Chief Financial Officer
Bassan Abraham, Director

How to read Form 4 transaction codes